Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
44 rows where has_cryoEM = 1, has_known_aptamer = 0 and surface_class = "A_assoc" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: pdb_count_total
surface_class 1
- A_assoc · 44 ✖
has_structure 1
- 1 44
has_known_aptamer 1
- - · 44 ✖
has_cryoEM 1
- 1 · 44 ✖
has_activation_state_pdb_pair 1
- 0 44
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P12883 | MYH7 | Myosin-7 | Tier 1 | 0.871 | 1 | A_assoc | 43 | 74.25 | 1 | 0 | 0 | 0 | 1 | hypertrophic cardiomyopathy | 0.9029865147265421 | |||
| P04180 | LCAT | Phosphatidylcholine-sterol acyltransferase | Tier 1.5 | 0.848 | 1 | A_assoc | 7 | 86.75 | 1 | 0 | 0 | 0 | 1 | Fish-eye disease | 0.8273460309828392 | |||
| Q15582 | TGFBI | Transforming growth factor-beta-induced protein ig-h3 | Tier 1.5 | 0.847 | 1 | A_assoc | 10 | 90.25 | 1 | 0 | 0 | 0 | 1 | lattice corneal dystrophy type I | 0.8242841141270143 | |||
| P07942 | LAMB1 | Laminin subunit beta-1 | Tier 1.5 | 0.84 | 1 | A_assoc | 3 | 76.69 | 1 | 0 | 0 | 0 | 1 | cobblestone lissencephaly without muscular or ocular involvement | 0.8016665947624902 | |||
| P00488 | F13A1 | Coagulation factor XIII A chain | Tier 1 | 0.838 | 1 | A_assoc | 15 | 90.88 | 1 | 0 | 0 | 0 | 1 | Factor XIII subunit A deficiency | 0.7939842013132387 | |||
| P35858 | IGFALS | Insulin-like growth factor-binding protein complex acid labile subunit | Tier 1.5 | 0.833 | 1 | A_assoc | 1 | 90.56 | 1 | 0 | 0 | 0 | 1 | Reduced insulin like growth factor binding protein acid labile subunit concentration | 0.7760522769257892 | |||
| O15230 | LAMA5 | Laminin subunit alpha-5 | Tier 1.5 | 0.828 | 1 | A_assoc | 2 | 79.12 | 1 | 0 | 0 | 0 | 1 | nephrotic syndrome, IIa 26 | 0.7594872666460903 | |||
| O60568 | PLOD3 | Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3 | Tier 1.5 | 0.815 | 1 | A_assoc | 18 | 91.38 | 1 | 0 | 0 | 0 | 1 | bone fragility with contractures, arterial rupture, and deafness | 0.7159150369336311 | |||
| P48200 | IREB2 | Iron-responsive element-binding protein 2 | Tier 1 | 0.799 | 1 | A_assoc | 1 | 86.75 | 1 | 0 | 0 | 0 | 1 | neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia | 0.664403876125082 | |||
| P02745 | C1QA | Complement C1q subcomponent subunit A | Tier 1 | 0.79 | 1 | A_assoc | 11 | 82.62 | 1 | 0 | 0 | 0 | 1 | C1Q deficiency 1 | 0.6319053256658114 | |||
| P02747 | C1QC | Complement C1q subcomponent subunit C | Tier 1 | 0.787 | 1 | A_assoc | 11 | 80.56 | 1 | 0 | 0 | 0 | 1 | C1Q deficiency | 0.6233532074390745 | |||
| A8K2U0 | A2ML1 | Alpha-2-macroglobulin-like protein 1 | Tier 1 | 0.764 | 1 | A_assoc | 5 | 80.5 | 1 | 0 | 0 | 0 | 1 | Otitis media | 0.5479914512784171 | |||
| Q08043 | ACTN3 | Alpha-actinin-3 | Tier 1 | 0.752 | 1 | A_assoc | 3 | 84.19 | 1 | 0 | 0 | 0 | 1 | Abnormality of the skeletal system | 0.5080072819822437 | |||
| P05161 | ISG15 | Ubiquitin-like protein ISG15 | Tier 1 | 0.74 | 1 | A_assoc | 22 | 85.88 | 1 | 0 | 0 | 0 | 1 | COVID-19 | 0.4668295741563516 | |||
| Q9BVC4 | MLST8 | Target of rapamycin complex subunit LST8 | Tier 1 | 0.733 | 1 | A_assoc | 45 | 91.62 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.4440338170862142 | |||
| O95970 | LGI1 | Leucine-rich glioma-inactivated protein 1 | Tier 1.5 | 0.697 | 1 | A_assoc | 9 | 92.56 | 1 | 0 | 0 | 0 | 0 | autosomal dominant epilepsy with auditory features | 0.8225657483127345 | |||
| P29460 | IL12B | Interleukin-12 subunit beta | Tier 1 | 0.687 | 1 | A_assoc | 20 | 91.12 | 1 | 0 | 0 | 0 | 0 | psoriasis | 0.7914863943708039 | |||
| P19876 | CXCL3 | C-X-C motif chemokine 3 | Tier 1.5 | 0.679 | 1 | A_assoc | 2 | 81.88 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.26311734927710556 | |||
| P19875 | CXCL2 | C-X-C motif chemokine 2 | Tier 1.5 | 0.674 | 1 | A_assoc | 4 | 81.62 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.24624512698601778 | |||
| Q2MKA7 | RSPO1 | R-spondin-1 | Tier 1 | 0.669 | 1 | A_assoc | 12 | 74.69 | 1 | 0 | 0 | 0 | 0 | palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome | 0.7285342885472184 | |||
| P12272 | PTHLH | Parathyroid hormone-related protein | Tier 1 | 0.666 | 1 | A_assoc | 11 | 62.88 | 1 | 0 | 0 | 0 | 0 | brachydactyly type E | 0.7203484375635054 | |||
| Q8N300 | SVBP | Small vasohibin-binding protein | Tier 1 | 0.649 | 1 | A_assoc | 24 | 85.06 | 1 | 0 | 0 | 0 | 0 | neurodevelopmental disorder with ataxia, hypotonia, and microcephaly | 0.6640118055835142 | |||
| O95631 | NTN1 | Netrin-1 | Tier 1.5 | 0.648 | 1 | A_assoc | 5 | 88.5 | 1 | 0 | 0 | 0 | 0 | mirror movements 4 | 0.6611393488240481 | |||
| Q9NWU2 | GID8 | Glucose-induced degradation protein 8 homolog | Tier 1.5 | 0.631 | 1 | A_assoc | 1 | 91.94 | 1 | 0 | 0 | 0 | 1 | Abnormality of the skeletal system | 0.10187555420552867 | |||
| Q9UHF0 | TAC3 | Tachykinin-3 | Tier 1 | 0.63 | 1 | A_assoc | 2 | 64.88 | 1 | 0 | 0 | 0 | 0 | hypogonadotropic hypogonadism 10 with or without anosmia | 0.5995324402695232 | |||
| P13727 | PRG2 | Bone marrow proteoglycan | Tier 1 | 0.629 | 1 | A_assoc | 9 | 75.94 | 1 | 0 | 0 | 0 | 1 | prostate cancer | 0.09730351635618993 | |||
| Q6IBW4 | NCAPH2 | Condensin-2 complex subunit H2 | Tier 1.5 | 0.62 | 1 | A_assoc | 1 | 62.41 | 1 | 0 | 0 | 0 | 0 | cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1 | 0.5674645203025676 | |||
| Q63HQ2 | EGFLAM | Pikachurin | Tier 1.5 | 0.574 | 1 | A_assoc | 3 | 80.56 | 1 | 0 | 0 | 0 | 0 | mathematical ability | 0.41387833248094535 | |||
| P06850 | CRH | Corticoliberin | Tier 1 | 0.562 | 1 | A_assoc | 5 | 61.97 | 1 | 0 | 0 | 0 | 0 | autosomal dominant nocturnal frontal lobe epilepsy | 0.37224647599732263 | |||
| Q7L8A9 | VASH1 | Tubulinyl-Tyr carboxypeptidase 1 | Tier 1 | 0.559 | 1 | A_assoc | 14 | 78.25 | 1 | 0 | 0 | 0 | 0 | Abnormality of the skeletal system | 0.36366533692746233 | |||
| P18509 | ADCYAP1 | Pituitary adenylate cyclase-activating polypeptide | Tier 1 | 0.559 | 1 | A_assoc | 12 | 62.56 | 1 | 0 | 0 | 0 | 0 | alcohol drinking | 0.36407172744864225 | |||
| O15240 | VGF | Neurosecretory protein VGF | Tier 1 | 0.545 | 1 | A_assoc | 5 | 60.44 | 1 | 0 | 0 | 0 | 0 | Abnormality of the skeletal system | 0.3156209584671744 | |||
| P0DMC3 | APELA | Apelin receptor early endogenous ligand | Tier 1 | 0.544 | 1 | A_assoc | 3 | 72.56 | 1 | 0 | 0 | 0 | 0 | attention deficit hyperactivity disorder | 0.3148526492327248 | |||
| M5A8F1 | ERVH48-1 | Suppressyn | Tier 1.5 | 0.519 | 1 | A_assoc | 1 | 74.94 | 1 | 0 | 0 | 0 | 0 | hypertension | 0.23115391486595976 | |||
| Q5T4W7 | ARTN | Artemin | Tier 1.5 | 0.512 | 1 | A_assoc | 5 | 75.0 | 1 | 0 | 0 | 0 | 0 | neurodegenerative disease | 0.20507822956537197 | |||
| Q99731 | CCL19 | C-C motif chemokine 19 | Tier 1 | 0.485 | 1 | A_assoc | 5 | 83.19 | 1 | 0 | 0 | 0 | 0 | neoplasm | 0.11672269610339286 | |||
| Q9H293 | IL25 | Interleukin-25 | Tier 1 | 0.485 | 1 | A_assoc | 3 | 79.0 | 1 | 0 | 0 | 0 | 0 | neoplasm | 0.11536752730834607 | |||
| Q7L2J0 | MEPCE | 7SK snRNA methylphosphate capping enzyme | Tier 1 | 0.485 | 1 | A_assoc | 5 | 62.66 | 1 | 0 | 0 | 0 | 0 | Neurodevelopmental delay | 0.11826555349910459 | |||
| Q8IZI9 | IFNL3 | Interferon lambda-3 | Tier 1.5 | 0.484 | 1 | A_assoc | 3 | 84.81 | 1 | 0 | 0 | 0 | 0 | hepatocellular carcinoma | 0.1145400757875244 | |||
| O00230 | CORT | Cortistatin | Tier 1.5 | 0.484 | 1 | A_assoc | 5 | 62.84 | 1 | 0 | 0 | 0 | 0 | neoplasm | 0.11461560504839655 | |||
| Q9Y5Q6 | INSL5 | Insulin-like peptide INSL5 | Tier 1.5 | 0.477 | 1 | A_assoc | 3 | 64.06 | 1 | 0 | 0 | 0 | 0 | polycystic ovary syndrome | 0.08868171274230166 | |||
| Q7Z4H4 | ADM2 | Protein ADM2 | Tier 1 | 0.469 | 1 | A_assoc | 2 | 58.38 | 1 | 0 | 0 | 0 | 0 | neoplasm | 0.06251866797932627 | |||
| P0DSE2 | TRB | M1-specific T cell receptor beta chain | Tier 1 | 0.45 | 1 | A_assoc | 5 | 90.12 | 1 | 0 | 0 | 0 | 0 | |||||
| P13848 | 7 | Capsid assembly scaffolding protein | Tier 1 | 0.45 | 1 | A_assoc | 15 | 1 | 0 | 0 | 0 | 0 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;